ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,201 to 2,220 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Palliative Care Team (PCTeam) vs Standard Care: Number of Nursing Home Residents in Moderate-to-severe Pain235 of 1,844

218 of 1,851

1.0 points

-1.2 to 3.1

3,695NCT01990742

Improving Palliative Care Through Teamwork

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Increased Circumferential Swelling at the Injection Limb(s)1,489 of 2,769

503 of 923

-0.7 points

-4.4 to 3.0

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Unsolicited Adverse Events (AEs)1,010 of 2,769

334 of 923

0.3 points

-3.3 to 3.8

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Serious Adverse Events (SAEs)47 of 2,769

18 of 923

-0.3 points

-1.4 to 0.6

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Physicians (MD) Office Visits668 of 2,769

205 of 923

1.9 points

-1.3 to 5.0

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting New Onset of Chronic Illness(es) (NOCDs)85 of 2,769

33 of 923

-0.5 points

-2.0 to 0.7

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Rash265 of 2,769

94 of 923

-0.6 points

-3.0 to 1.5

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits137 of 2,769

54 of 923

-0.9 points

-2.8 to 0.7

3,692NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Emergency or Urgent Revascularization7 of 2,774

2 of 917

0.0 points

-0.6 to 0.3

3,691NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Worker Who Perform Hand Hygiene on Exit From Any Room1,525 of 1,785

1,587 of 1,897

1.8 points

-0.6 to 4.1

3,682NCT03119389

Direct Gloving Strategy: A Cluster-randomized Trial

Influenza Vaccine vs Placebo: deaths from any cause1 of 1,829

0 of 1,841

0.1 points

-0.2 to 0.3

3,670NCT00566345

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Influenza Vaccine vs Placebo: serious adverse events3 of 1,829

0 of 1,841

0.2 points

-0.1 to 0.5

3,670NCT00566345

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Intent-to-Treat (ITT) Atrasentan vs Intent-to-Treat Placebo: Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)152 of 1,834

192 of 1,834

-2.2 points

-4.1 to -0.3

3,668NCT01858532

Study Of Diabetic Nephropathy With Atrasentan

Facility-based Screening vs Contact Screening: Treatment Initiation Ratio in Facility Versus Contact Investigation Clinics1,929 of 1,929

1,726 of 1,726

0.0 points

-0.2 to 0.2

3,655NCT02808507

Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa

XIENCE V® vs TAXUS™ EXPRESS 2™: serious adverse events913 of 2,436

468 of 1,214

-1.1 points

-4.4 to 2.3

3,650NCT00307047

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

Canadian Td Vaccine Group vs United States Td Vaccine Group: serious adverse events58 of 2,950

44 of 700

-4.3 points

-6.4 to -2.7

3,650NCT00601835

Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td

Arm I vs Arm II: Breast Cancer-specific Mortality155 of 1,824

160 of 1,825

-0.3 points

-2.1 to 1.6

3,649NCT01101438

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Metformin vs Placebo: deaths from any cause201 of 1,824

198 of 1,825

0.2 points

-1.9 to 2.2

3,649NCT01101438

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

HEART Care vs Usual Care: MACE (Major Adverse Cardiac Events)345 of 1,821

405 of 1,827

-3.2 points

-5.8 to -0.6

3,648NCT01756846

Impact on Management of the HEART Risk Score in Chest Pain Patients

HEART Care vs Usual Care: deaths from any cause5 of 1,821

9 of 1,827

-0.2 points

-0.7 to 0.2

3,648NCT01756846

Impact on Management of the HEART Risk Score in Chest Pain Patients

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=111"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=111

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01990742-2bcf7e19",
        "title": "Palliative Care Team (PCTeam) vs Standard Care: Number of Nursing Home Residents in Moderate-to-severe Pain",
        "summary": "235 of 1844 against 218 of 1851; risk difference 1.0 points, 95% interval -1.2 to 3.1; NCT01990742, Improving Palliative Care Through Teamwork",
        "record": "/library/comparisons/NCT01990742-2bcf7e19",
        "nct_id": "NCT01990742",
        "kind": "outcome",
        "participants": 3695,
        "risk_difference": {
          "value": 0.009666170950567862,
          "lower": -0.011511383235578907,
          "upper": 0.03085901423225643
        },
        "group_1": "235 of 1,844",
        "group_2": "218 of 1,851",
        "difference": "1.0 points",
        "interval": "-1.2 to 3.1",
        "trial_title": "Improving Palliative Care Through Teamwork"
      },
      {
        "id": "NCT00289783-0806ded5",
        "title": "Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Increased Circumferential Swelling at the Injection Limb(s)",
        "summary": "1489 of 2769 against 503 of 923; risk difference -0.7 points, 95% interval -4.4 to 3.0; NCT00289783, Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine",
        "record": "/library/comparisons/NCT00289783-0806ded5",
        "nct_id": "NCT00289783",
        "kind": "outcome",
        "participants": 3692,
        "risk_difference": {
          "value": -0.007222824124232585,
          "lower": -0.044131233620242474,
          "upper": 0.029955764467501693
        },
        "group_1": "1,489 of 2,769",
        "group_2": "503 of 923",
        "difference": "-0.7 points",
        "interval": "-4.4 to 3.0",
        "trial_title": "Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=112",
  "request_id": "wjZV1AHe2YtO-Y3_"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?